Acalabrutinib-induced multiple oral ulcerations: report of a case and review of the literature.
文献摘要
Acalabrutinib, a Bruton's tyrosine kinase inhibitor, is an effective therapy for hematologic malignancies. Although generally well-tolerated, it may cause adverse events including rare oral toxicities. A 94-year-old woman with a 13-year history of chronic lymphocytic leukemia presented with severe oral pain and dysphagia. Previously, multiple agents had been administered, including ibrutinib, and most recently acalabrutinib (100 mg two times per day), which was discontinued following the onset of hematuria and painful oral ulcerations. Examination revealed deep ulcerations affecting the hard palate, dorsum of tongue, and buccal mucosa. Hematologic evaluation showed leukocytosis (WBC 63 × 10⁹/L) without neutropenia/thrombocytopenia. A customized topical mouthwash achieved near-complete resolution of oral lesions within 2 weeks. Reintroduction of acalabrutinib, 7 months later, caused milder oral ulcerations which resolved with the same regimen without discontinuation of acalabrutinib. Causality was supported by the temporal association, resolution upon withdrawal, and recurrence on rechallenge. This case reports acalabrutinib-associated off-target kinase effects impairing mucosal healing.